noom glp-1 rx Eyes GLP-1s for Longevity, Not Just Weight Loss Noom Unveils Two New Enterprise

doi: 10.1177/1060028020935105 127 LinSDengYHuangJLiMSoorannaSRQinMet al

Further inquiries can be directed to the corresponding author

TripleHormone-Receptor Agonist Retatrutide

B 57 , 289300 (1995)

A recent study that was published in the New England Journal of Medicine (and also funded by Novo Nordisk) evaluated about 10,000 participants who had type 2 diabetes and also atherosclerosis or chronic kidney disease, or both

Within the findings were several considerations for patients and payers: High costs for GLP-1 medications ranked as respondents top concern (followed by lack of control over who is prescribed the medications) 93% covered GLP-1s for management of diabetes in the previous plan year